Avience Biomedicals shares may make a strong debut as GMP signals 62% premium ahead of listing (opens original article in a new tab)

Avience Biomedicals is set to make its stock market debut on NSE SME with a 62% grey market premium, following strong IPO subscription across all investor categories. The IPO proceeds will fund a new manufacturing facility and other corporate needs. The grey market premium suggests optimism but is not a guarantee of listing gains.

• Avience Biomedicals is set to debut on NSE SME with a grey market premium of 62% over the issue price of Rs 208
• The IPO received 385.32 times subscription with strong participation from all investor categories
• IPO proceeds will fund a new manufacturing facility, working capital, and general corporate purposes
• Grey market premium indicates investor optimism but is not a guarantee of listing gains